Pharma Deals Review, Vol 2007, No 87 (2007)

Font Size:  Small  Medium  Large

Bayer and Nektar Collaborate on Inhaled Pneumonia Drug

Business Review Editor

Abstract


Bayer HealthCare and Nektar Therapeutics have agreed to develop and commercialize NKTR-061 (inhaled amikacin) for adjunctive treatment of ventilated patients with hospital-acquired Gram-negative pneumonias.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.